Navigation Links
Well-informed patients key to accepting gene-based drug dosing

A new study out of Western University (London, Canada) illustrates the need for a lot more education around pharmacogenetics (PGx) the study of how a patient's genes can affect drug reaction and dosage. PGx promises to optimize patient response to therapy, but this is the first study to really investigate how patients perceive this kind of genetic testing, and whether those perceptions differ when it comes to parents and their children. The research, led by Dr. Michael Rieder of Western's Schulich School of Medicine & Dentistry is published in the journal Pediatrics.

"Pharmacogenetic testing has become widely used and gene-based drug dosing is becoming a reality for a number of common health problems. This study confirms what we suspected; Whether or not you're a parent, your degree of acceptability of genetic testing was determined by your knowledge of it. That is to say if you understand what the test is for, and the concept of gene-based drug dosing, you're far more open to it, than if you don't understand it," said Dr. Rieder, a professor in the Departments of Paediatrics, and Physiology and Pharmacology.

The researchers surveyed three groups including: 236 medical students representing those having greater educational exposure to PGx, 1,226 lay parents and 105 lay people without children. A second survey was completed by 229 parents. The surveys didn't use PGx but rather, asked about "DNA testing to guide therapy." The study concluded that the acceptability of PGx testing, either for oneself or one's child, seemed to depend on baseline PGx knowledge, but not on parenthood.

The main concern for all respondents was the need for informed consent. Other findings included:

  • More acceptance for PGx when the disease was severe

  • Strong desire/demand for separate consent for PGx testing

  • More education about PGx needed in medical schools

  • Acceptability of genetic testing didn't differ whether for the parent or the child

Dr. Rieder says PGx should take a lesson from pediatric oncology. He says health care workers in that division do a good job in the way they frame the discussions around care, treatment, and consent. "When they have to make a diagnosis, they spend a lot of time explaining what tests they're going to do, the risks, and what therapies are available. And they're successful. Their patients comply with treatment, they get involved in studies, they're informed, and they want to know what's going on."

Contact: Kathy Wallis
519-661-2111 x81136
University of Western Ontario

Related biology news :

1. Breast cancer patients place huge emphasis on gene expression profiling test
2. Spinal stimulation helps 4 patients with paraplegia regain voluntary movement
3. Key genetic mutations could be new hope for adrenocortical tumor patients
4. Cause for exaggerated insulin response in subset of bariatric surgery patients identified
5. Faster genetic testing method will likely transform care for patients with breast cancer
6. Certain genetic variants may put bladder cancer patients at increased risk of recurrence
7. How the science of deer hunting can help patients with diabetes
8. Diaphragm pacing in spinal cord injury successful in weaning patients from ventilators
9. Vitamin A used in acne medicines may help autoimmune and transplant patients
10. Gastric banding patients should closely monitor nutrition following surgery
11. Identified a subgroup of schizophrenia patients with motor disorders
Post Your Comments:
Related Image:
Well-informed patients key to accepting gene-based drug dosing
(Date:6/21/2016)... June 21, 2016 NuData Security announced today ... role of principal product architect and that ... of customer development. Both will report directly to ... The moves reflect NuData,s strategic growth in its ... high customer demand and customer focus values. ...
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network for ... Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is to ... are designed, built and brought to market. , The Design Lab is Supplyframe’s ...
(Date:6/23/2016)... Durham, NC (PRWEB) , ... June 23, 2016 , ... ... Odense University Hospital in Denmark detail how a patient who developed lymphedema after being ... (fat) tissue. The results could change the paradigm for dealing with this debilitating, frequent ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
Breaking Biology Technology: